JP2013533882A - 肺高血圧症を処置するためのa2bアデノシン受容体アンタゴニストの使用 - Google Patents

肺高血圧症を処置するためのa2bアデノシン受容体アンタゴニストの使用 Download PDF

Info

Publication number
JP2013533882A
JP2013533882A JP2013518651A JP2013518651A JP2013533882A JP 2013533882 A JP2013533882 A JP 2013533882A JP 2013518651 A JP2013518651 A JP 2013518651A JP 2013518651 A JP2013518651 A JP 2013518651A JP 2013533882 A JP2013533882 A JP 2013533882A
Authority
JP
Japan
Prior art keywords
optionally substituted
methyl
dione
pyrazol
trihydropurine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013518651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533882A5 (cg-RX-API-DMAC7.html
Inventor
ルイス ベラディネッリ,
デュワン チェン,
チョン ホンヤン,
Original Assignee
ギリアード サイエンシーズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ, インコーポレイテッド filed Critical ギリアード サイエンシーズ, インコーポレイテッド
Publication of JP2013533882A publication Critical patent/JP2013533882A/ja
Publication of JP2013533882A5 publication Critical patent/JP2013533882A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013518651A 2010-06-30 2011-06-29 肺高血圧症を処置するためのa2bアデノシン受容体アンタゴニストの使用 Pending JP2013533882A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36028910P 2010-06-30 2010-06-30
US61/360,289 2010-06-30
PCT/US2011/042379 WO2012003220A1 (en) 2010-06-30 2011-06-29 Use of a2b adenosine receptor antagonists for treating pulmonary hypertension

Publications (2)

Publication Number Publication Date
JP2013533882A true JP2013533882A (ja) 2013-08-29
JP2013533882A5 JP2013533882A5 (cg-RX-API-DMAC7.html) 2014-08-14

Family

ID=44343985

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518651A Pending JP2013533882A (ja) 2010-06-30 2011-06-29 肺高血圧症を処置するためのa2bアデノシン受容体アンタゴニストの使用

Country Status (11)

Country Link
US (1) US20120003329A1 (cg-RX-API-DMAC7.html)
EP (1) EP2595630A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013533882A (cg-RX-API-DMAC7.html)
KR (1) KR20130088834A (cg-RX-API-DMAC7.html)
CN (1) CN103237548A (cg-RX-API-DMAC7.html)
AU (1) AU2011271510A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012032766A2 (cg-RX-API-DMAC7.html)
CA (1) CA2802891A1 (cg-RX-API-DMAC7.html)
EA (1) EA201291274A1 (cg-RX-API-DMAC7.html)
MX (1) MX2012015112A (cg-RX-API-DMAC7.html)
WO (1) WO2012003220A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024508553A (ja) * 2021-03-05 2024-02-27 トスク インコーポレーテッド 薬物誘発性肺機能障害の予防又は処置のためのウリジンホスホリラーゼ阻害剤

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
JP2017048116A (ja) * 2014-01-10 2017-03-09 国立研究開発法人国立国際医療研究センター 肺高血圧症治療薬
US20210038510A1 (en) * 2018-02-08 2021-02-11 Pulmokine, Inc. Formulations of kinase inhibitors and prostanoids
JP7849948B2 (ja) * 2018-03-05 2026-04-22 テオン セラピューティクス,インク. アデノシン受容体アンタゴニストおよびその使用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229106A1 (en) * 2001-11-09 2003-12-11 Rao Kalla A2B adenosine receptor antagonists
JP2005509036A (ja) * 2001-11-09 2005-04-07 シーブイ・セラピューティクス・インコーポレイテッド A2bアデノシン受容体アンタゴニスト
US20060293283A1 (en) * 2005-06-16 2006-12-28 Rao Kalla Prodrugs of A2B adenosine receptor antagonists
JP2007506752A (ja) * 2003-09-24 2007-03-22 コゼリクス、 インク. 肺動脈高血圧症を治療するための併用療法におけるイロプロスト
US20070072843A1 (en) * 2005-02-25 2007-03-29 Guoquan Wang Pyridyl substituted xanthines

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US6117878A (en) 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
ATE307132T1 (de) 2001-06-29 2005-11-15 Cv Therapeutics Inc Purin derivate als a2b adenosin rezeptor antagonisten
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
DE10303639B4 (de) 2003-01-30 2016-05-25 Zf Friedrichshafen Ag Vorrichtung zur Steuerung einer hydraulisch betätigbaren Kupplung eines Automatgetriebes
EP2311462A1 (en) * 2004-10-15 2011-04-20 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
JP2010512414A (ja) * 2006-12-12 2010-04-22 ギリード・コロラド・インコーポレーテッド 肺高血圧を処置するための組成物
JP5460690B2 (ja) 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229106A1 (en) * 2001-11-09 2003-12-11 Rao Kalla A2B adenosine receptor antagonists
JP2005509036A (ja) * 2001-11-09 2005-04-07 シーブイ・セラピューティクス・インコーポレイテッド A2bアデノシン受容体アンタゴニスト
JP2007506752A (ja) * 2003-09-24 2007-03-22 コゼリクス、 インク. 肺動脈高血圧症を治療するための併用療法におけるイロプロスト
US20070072843A1 (en) * 2005-02-25 2007-03-29 Guoquan Wang Pyridyl substituted xanthines
US20060293283A1 (en) * 2005-06-16 2006-12-28 Rao Kalla Prodrugs of A2B adenosine receptor antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6015021192; J Clin Invest Vol.16, No.8, 2006, p.2173-82 *
JPN6015021194; Respir Physiol Neurobiol Vol.170, No.1, 201001, p.32-6 *
JPN6015021196; Am J Physiol Lung Cell Mol Physiol Vol.294, No.1, 2008, p.L24-33 *
JPN6015021198; Pediatr Int Vol.47, No.3, 2005, p.242-7 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024508553A (ja) * 2021-03-05 2024-02-27 トスク インコーポレーテッド 薬物誘発性肺機能障害の予防又は処置のためのウリジンホスホリラーゼ阻害剤

Also Published As

Publication number Publication date
EA201291274A1 (ru) 2013-12-30
EP2595630A1 (en) 2013-05-29
CN103237548A (zh) 2013-08-07
MX2012015112A (es) 2013-05-28
CA2802891A1 (en) 2012-01-05
WO2012003220A1 (en) 2012-01-05
AU2011271510A1 (en) 2013-01-10
KR20130088834A (ko) 2013-08-08
US20120003329A1 (en) 2012-01-05
BR112012032766A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
JP5250848B2 (ja) A2bアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法
RU2374247C2 (ru) Способ получения антагонистов аденозиновых рецепторов a2b и промежуточные продукты
ES2959419T3 (es) Formulaciones secas por aspersión
RU2391103C2 (ru) Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b
EP3007689B1 (en) Non-selective kinase inhibitors
US20120003329A1 (en) Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension
AU2012254057B2 (en) Use of A2B adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients
US20190125756A1 (en) Method of treating hypertension
AU2012261721A1 (en) Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists
HK40036372B (zh) 喷雾干燥制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151027